Renu Govindaiah, MD
Allergy · Springfield, ILNPI 1477553931
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 66.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $5,689 and has fallen 79.8% since, to $1,151 in 2025.
Across 141 payments — averaging $51.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- CSL Behring$455
- AstraZeneca$399
- Takeda Pharmaceuticals U.S.A., Inc.$278
- Optinose US, Inc.$257
- Sanofi$213
- plus $798 from 13 others
Across 14 payments — averaging $1758.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$25K
What the payments were for
- Consulting fees$3,74552%
- Speaking & faculty fees$250%
- Travel & lodging$5287%
- Food & beverage$2,80539%
- Education$971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 17 | $4,800 |
| CSL Behring | 22 | $455 |
| AstraZeneca | 14 | $399 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $278 |
| Optinose US, Inc. | 19 | $257 |
| Sanofi | 12 | $213 |
| GSK | 12 | $206 |
| Regeneron Healthcare Solutions, Inc. | 6 | $143 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $92 |
| Boehringer Ingelheim | 4 | $63 |
| Pfizer | 4 | $61 |
| Novartis | 3 | $59 |
| Cycle Pharmaceuticals Inc | 3 | $50 |
| Greer Laboratories, Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,200 in reported general payments places this provider in the 75th percentile of 47 allergy providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 11 | $770,299 |
| Dupixent SyringeDupilumab | 23 | $125,801 |
| XolairOmalizumab | 23 | $113,558 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $70,061 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $42,234 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $18,269 |
| Arnuity ElliptaFluticasone Furoate | 34 | $14,552 |
| Spiriva RespimatTiotropium Bromide | 17 | $8,798 |
| DuleraMometasone/Formoterol | 13 | $8,495 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $4,059 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $3,796 |
| Epinephrine | 21 | $3,665 |
| Azelastine Hcl | 83 | $2,953 |
| Fluticasone Propionate | 92 | $1,689 |
| Montelukast Sodium | 253 | $1,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $455 | $770,29911 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $206 | $75,055109 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $278 | $70,06113 claims |
| Boehringer IngelheimSpiriva Respimat | $63 | $8,79817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 47 allergy providers in Illinois.
Other allergy in Springfield
- Ewa SchaferGlenview$165K
- Brian RotskoffChicago$82K
- Bruce BochnerChicago$43K
- Mark MillerHoffman Estates$17K
- Mohammad GhaniWestchester$16K
- Sai NimmagaddaOrland Park$14K
- Archana NarayanJoliet$11K
- Alan ResnickOrland Park$9K
- Alex ThomasChicago$9K
- Lee SoninSchaumburg$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.